Stylianos Kakolyris

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer

Nikolaos Xenidis, Michail Ignatiadis, Stella Apostolaki et al. · Journal of Clinical Oncology · 2009 · 241 citations · Full text

Medicine, Cancer Biology, Oncology +15

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

D. Mavroudis, Emmanouil Saloustros, N. Malamos et al. · Annals of Oncology · 2015 · 164 citations

Medicine, Oncology, Breast Oncology +15

Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial

Vassilis Georgoulias, Alexandros Ardavanis, Xanthi Tsiafaki et al. · Journal of Clinical Oncology · 2005 · 163 citations · Full text

Medicine, Oncology, Pharmacology +12